Zebrafish Model

Key regulators of bone formation are highly conserved between mammals and teleosts. The corresponding orthologs share significant sequence similarities and an overlap in expression patterns when compared to mammals.

Cranial cartilage is the first skeletal structure to be detected as early as 3 days post-fertilization, while first calcified intramembranous bone structures start to form at about the same time.

Due to its rapid generation time, large offspring numbers, external development, transparency and the availability of genetic maps, the zebrafish is a very attractive model system to study the function of genes involved in bone formation.

Transgenic zebrafish lines represent unique tools to follow osteoblasts in vivo and to analyze their function in wild type or mutant backgrounds.

This animal model can be used to evaluate drug or treatment effects on cartilage and bone formation by measuring:

  • The intensity and progression of bone formation
  • Their level of ossification
  • The level of calcification
  • Morphometric analysis

Using this model, researchers from GIGA have evaluated the physiological consequences of altered gravity on bone formation and more generally on whole genome gene expression.

For more info on our zebrafish facility, click here.

Related articles

PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

Liège (Belgium), 21st January 2019. PDC*line Pharma is delighted to announce, that the company is now accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for the Quality Control and Release activities of its anticancer agent PDC*lung, intended for the treatment of patients with lung cancer.  PDC*line Pharma is developing a new

Read more
PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

First Congress in Health Simulation

The Medical Simulation Center of the University of Liège organizes its first congress in Health Simulation: “Towards evidence-based simulation”. Event will be held on Thursday, March 28th, 2019 in the faculty of medicine amphitheatres of Liège University, located on Sart-Tilman campus. Several themes will be discussed: Evidence-based Innovations and advances in simulation Medical education –

Read more
First Congress in Health Simulation

New University Certificate for clinical trials

The Clinical Sciences Department of the Medicine Faculty of the University of Liège organizes from the academic year 2018-2019 a University Certificate in clinical trials. More information is available in this folder

Read more
New University Certificate for clinical trials